Lupin recalls Quinapril tablets from US market

Pharma major Lupin has said its US subsidiary Lupin Pharmaceuticals Inc has initiated voluntary

RELATED ARTICLES

recall of multiple lots of Quinapril Tablets USP from the US market after failing impurity specification test.

According to information available with the US Food and Drug Administration (FDA), the recall was initiated by the company last September and as many as 53,160 bottles (30,264 bottles of 5 mg and 22,896 bottles of 10 mg) of both the drugs (90-count bottles) are being recalled under Class-II classification.

In 2006, Lupin received final approval from the FDA for its Abbreviated New Drug Application (ANDA) for Quinapril Tablets USP in 5 mg, 10 mg, 20 mg and 40 mg strengths. The drug is indicated to treat hypertension.

"During stability testing an unknown impurity was found to be above the specification limit at 36 month test interval," FDA said citing the cause for the recall.

According to the US health regulator, Class II recall is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

Both the drugs were manufactured by Lupin at its Goa facility.

When contacted, Lupin in a statement said: "This is an old event and a voluntary recall for a small batch of Quinapril Tablets 5 mg and 10 mg strengths; a precaution on our part, and of no business consequence."

Lupin shares today settled lower by 1.14 per cent at Rs 865.90 apiece on the BSE.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • Child abuse needs to be tackled with the seriousness it deserves

    The Bangalore rape case has again brought into focus an issue we Indians forever shy away from facing up to — child sexual abuse.

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Varun Dutt

<b>Riskfactor</b>: THE BASE RATE BIAS

Base rate fallacy, also called base rate neglect or base ...

Parvez Imam

Revisiting history can do us all good

We often think that we understand history. We read it ...

Bubbles Sabharwal

Your happiness doesn’t depend on your needs

They are two different words (and even worlds) altogether: having ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture